Platinum derivatives: a multidisciplinary approach

J BUON. 2017 May-Jun;22(3):568-577.

Abstract

Cancer is one of the most difficult diseases to be treated. The particularities regarding the tumors' occurrence mechanism, their evolution under chemotherapy, disease-free interval, but also the increasing number of patients make cancer an intensively studied health domain. Although introduced in therapy since the early 80s, platinum derivatives play an essential role in anticancer therapy. Their use in therapy resulted in improving the patient quality of life and prolonging disease-free interval, which makes them still a benchmark for other anticancer compounds. However, adverse reactions and allergic reactions are a major impediment in therapy with platinum derivatives. This paper summarizes data about platinum derivatives through a multidisciplinary approach, starting from a chemical point of view and on to their mechanism of action, mechanism of cellular resistance, predictive factors for the outcome of chemotherapy such as micro RNAs (miRNAs), tumor suppressor protein p53, and the excision repair cross-complementing 1 protein (ERCC1).

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Carboplatin / adverse effects
  • Carboplatin / chemistry
  • Carboplatin / pharmacology
  • Cisplatin / adverse effects
  • Cisplatin / chemistry
  • Cisplatin / pharmacology
  • Drug Resistance, Neoplasm
  • Humans
  • Organoplatinum Compounds / pharmacology*
  • Oxaliplatin / adverse effects
  • Oxaliplatin / chemistry
  • Oxaliplatin / pharmacology
  • Tumor Suppressor Protein p53 / physiology

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Tumor Suppressor Protein p53
  • Oxaliplatin
  • Carboplatin
  • Cisplatin